 PRINCETON, N.J., June 9, 2021 PRNewswire -- Soligenix, Inc. Nasdaq: SNGX Soligenix or the Company, a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received approximately 865,000, net of transaction costs, in non-dilutive financing via the state of New Jerseys Technology Business Tax Certificate Transfer Program. 